Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mammalian recombinant coagulation proteins: structure and function.

G C White1, E M Pickens, D K Liles

  • 1Department of Medicine, University of North Carolina at Chapel Hill 27599-7035, USA.

Transfusion Science
|May 7, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Case of Functional, Simulating Organic Disease of the Heart.

Western journal of medicine and surgery·2024
Same author

Immune tolerance induction: What have we learned over time?

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Harold Ross Roberts, M.D: inspirational mentor, consummate physician, superb scientist (1930-2017).

Journal of thrombosis and haemostasis : JTH·2017
Same author

Future developments in the treatment of haemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

A multicenter study of recombinant factor VIII (Recombinate(TM) ) in previously treated patients with hemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

Discontinuous automated calcium supplementation during thrombocytapheresis with the haemonetics MCS+ version C.

Transfusion science·2002
Same journal

Is Brazil entering a new age?

Transfusion science·2001
Same journal

Is Brazil entering a new age?

Transfusion science·2001
Same journal

Post-transfusion thrombocytopenia in recipients with anti-HLA antibody.

Transfusion science·2000
Same journal

The design and properties of 3-hydroxypyridin-4-one iron chelators with high pFe(3+) values.

Transfusion science·2000
Same journal

A relationship between glucose metabolism and NO-mediated iron mobilization from cells.

Transfusion science·2000
See all related articles

Recombinant DNA technology produces synthetic clotting factors that are structurally and functionally similar to natural ones. These recombinant proteins offer a safe and effective alternative for treating coagulation disorders.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Hematology

Background:

  • Recombinant DNA technology enables the synthesis of therapeutic proteins.
  • Plasma-derived clotting factors carry risks of infectious agents.
  • Synthetic proteins offer a potentially safer alternative.

Purpose of the Study:

  • To evaluate the structural and functional comparability of recombinant clotting factors to their plasma-derived counterparts.
  • To assess the clinical efficacy and safety of recombinant clotting factors.

Main Methods:

  • Comparison of primary, secondary, and tertiary structures of recombinant and plasma clotting factors.
  • Analysis of post-translational modifications (glycosylation, carboxylation, hydroxylation, sulfation, phosphorylation).
  • Assessment of specific clotting activity and in vivo recovery after infusion.

Related Experiment Videos

Main Results:

  • Recombinant clotting factors (VIII, IX, VIIa, von Willebrand factor) share primary sequences with plasma factors.
  • Post-translational modifications are largely similar but exhibit some variations.
  • Functional clotting activity is equivalent, though some modifications may impact in vivo recovery.
  • Clinical use demonstrates effective correction of deficiencies, similar to plasma factors.

Conclusions:

  • Recombinant clotting factors are structurally and functionally comparable to plasma-derived proteins.
  • While minor differences in post-translational modifications exist, they generally maintain efficacy.
  • Recombinant DNA technology holds significant promise for treating coagulation disorders safely and effectively.